EGFR and Miyoshi myopathy: We next evaluated the potential impact of ERBB1/EGFR expression levels on the PFS and OS of newly diagnosed MM patients by comparing the PFS and OS times for MM patients with the highest expression level of ERBB1/EGFR (i.e., top 40% with the highest observed expression level; N = 112) with the PFS and OS times for MM patients with the lowest expression level of ERBB1/EGFR (i.e., bottom 40% with the lowest observed expression level; N = 112).